DFI and Aneuploidies

NCT06279715 | Completed

• 1 other identifier: 3437
• Study Type: observational
• Target: 537
• Locations: 1 country
• Sites: 1

Brief Summary

IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure. Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes.

Conditions

Embryo Disorder

Outcome Measures

Primary Outcomes (1)

• DFI association and aneuploidy

  Segmental aneuploidy is associated with high levels of sperm DNA fragmentation index

  Up to 3 weeks after embryo fertilization

Interventions

Preimplantation Genetic Testing for Aneuploidy OTHER

PGT-A typically involves the biopsy of three to eight cells from the developing embryo after approximately five days of culture. This technology also allows for the identification of segmentally aneuploid embryos.

Eligibility Criteria

• Age: 18 Years - 43 Years
• Sex: all
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Data spreadsheet from October 2020 to December 2023 consisting of more than 800 medical charts.

You may qualify if:

• IVF cycle completed at clinique ovo
• Maternal age between 18 to 43 years included
• PGT-A done on all embryos
• Recent DFI within 1 year of the IVF cycle

You may not qualify if:

• Sperm donation

Sponsors & Collaborators

• Clinique Ovo: lead

Study Sites (1)

Clinique ovo

Montreal, Quebec, H4P 2S4, Canada

Location

Study Officials

• Isaac-Jacques Kadoch, MD

  Clinique Ovo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 16, 2024
• First Posted: February 28, 2024
• Study Start: January 19, 2024
• Primary Completion: November 14, 2024
• Study Completion: November 14, 2024
• Last Updated: July 31, 2025

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)